Table of Contents Author Guidelines Submit a Manuscript
Oxidative Medicine and Cellular Longevity
Volume 2016, Article ID 1973834, 18 pages
http://dx.doi.org/10.1155/2016/1973834
Review Article

New Insights into the Role of Oxidative Stress Mechanisms in the Pathophysiology and Treatment of Multiple Sclerosis

Department of Neurology in Zabrze, Medical University of Silesia, ul. 3 Maja 13-15, 41-800 Zabrze, Poland

Received 18 May 2016; Revised 5 August 2016; Accepted 19 September 2016

Academic Editor: Capucine Trollet

Copyright © 2016 Bożena Adamczyk and Monika Adamczyk-Sowa. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Multiple sclerosis (MS) is a multifactorial disease of the central nervous system (CNS) characterized by an inflammatory process and demyelination. The etiology of the disease is still not fully understood. Therefore, finding new etiological factors is of such crucial importance. It is suspected that the development of MS may be affected by oxidative stress (OS). In the acute phase OS initiates inflammatory processes and in the chronic phase it sustains neurodegeneration. Redox processes in MS are associated with mitochondrial dysfunction, dysregulation of axonal bioenergetics, iron accumulation in the brain, impaired oxidant/antioxidant balance, and OS memory. The present paper is a review of the current literature about the role of OS in MS and it focuses on all major aspects. The article explains the mechanisms of OS, reports unique biomarkers with regard to their clinical significance, and presents a poorly understood relationship between OS and neurodegeneration. It also provides novel methods of treatment, including the use of antioxidants and the role of antioxidants in neuroprotection. Furthermore, adding new drugs in the treatment of relapse may be useful. The article considers the significance of OS in the current treatment of MS patients.

1. Introduction

Multiple sclerosis (MS) is a multifactorial disease of the central nervous system (CNS) in which both inflammatory and neurodegenerative processes occur simultaneously. In the course of the disease inflammation is decreased whereas the degeneration of the CNS progresses [1]. Several forms of MS are distinguished. These are the following: RRMS (relapsing-remitting MS), SPMS (secondary progressive MS), and PPMS (primary progressive MS). In RRMS an inflammatory process predominates whereas in SPMS and PPMS a neurodegenerative process is more strongly expressed. Relapses defined as episodic exacerbations of neurological signs or symptoms are characteristic of RRMS [2]. Between the relapses patients fully or partially recover from the deficit. The most common form of MS is RRMS which may progress into SPMS after years of remission; SPMS is a natural consequence of RRMS in which relapses decrease and finally disappear over time. In PPMS relapses do not occur from the onset of MS. Progressive axonal loss typically accompanies the PPMS form [3]. As a result, in the course of progressive forms the dominance of neurodegeneration is related to a lack of functional improvement [4, 5].

The ultimate causative factor of this process remains unknown. However, it is suspected that the development of MS may be affected by genetic and environmental factors. Recent observations confirm the fact that oxidative stress (OS) became an important factor associated with the development of demyelination [1, 6, 7].

2. The Importance of OS in MS

The inflammatory component in MS is important not only due to axonal and neuronal loss but also due to the fact that it starts the degenerative cascade in the early stage of MS [6]. Interestingly, persistent hyperactivation of oxidative enzymes suggests an “OS memory” in chronic neuroinflammation [62]. The induction of the activation of microglia and mitochondrial dysfunction plays a particular role in inflammatory processes. Microglia activated by T-lymphocytes release proteolytic enzymes, cytokines, oxidative products, and free radicals. On the other hand, microglia have a number of protective properties [59] such as a positive role in the promotion of neuroprotection, lowering inflammation, and stimulation of tissue repair [60].

The development of neurodegeneration in MS is a complex process that may be related to primary apoptosis, synaptopathy, and excitotoxicity associated with glutamate overload, ionic channel dysfunction, calcium overload, mitochondriopathy, proteolytic enzyme production, and activation of apoptotic pathways. It is also important that mitochondrial dysfunction results in an increased production of reactive oxygen species (ROS), which is detrimental to neurons and glia [12, 61]. On the other hand, OS damages the mitochondria, which disrupts the transport of adenosine triphosphate along the axon, and consequently leads to neurodegeneration [6365]. Importantly, the neurodegenerative process is complicated and still poorly understood.

For a better understanding of the redox processes in the course of MS, some general issues related to OS need to be addressed.

2.1. The Mechanisms of OS

The brain tissue is very sensitive to the action of radicals due to its high demand for oxygen and a limited possibility of obtaining antioxidants. An imbalance between free radical production and antioxidative defense results in OS and nitrosative stress [18, 66].

A free radical can be defined as an unstable, short-lived, and highly reactive atom or molecule [18]. Free radicals, ROS and reactive nitrogen species (RNS), can affect important classes of biological molecules, thus leading to multiple lipid and protein damage via peroxidation and nitration processes [18].

The levels of ROS/RNS are involved in various physiological functions such as the immune function (i.e., defense against pathogenic microorganisms). They are also involved in a number of cellular signaling pathways, in the mitogenic response, and in the redox regulation [18, 67, 68]. Both ROS and RNS can be classified into two groups, that is, radicals and nonradicals [8, 10, 18, 69] (Figure 1).

Figure 1: Reactive oxygen species (ROS) and reactive nitrogen species (RNS) [5, 5961]. The classification of ROS and RNS depended on having an unpaired electron. Nonradial species exists without an unpaired electron.

The endogenous sources of ROS include mitochondria, peroxisomes, endoplasmic reticulum, and phagocytic cells. Macrophages constitute a major factor responsible for the production of ROS [10] due to high oxygen consumption [6, 18].

The redox reaction involves mainly a superoxide radical, hydrogen peroxide, hydroxyl radical anion, nitric oxide (NO), peroxynitrite [10, 13], peroxyl radical, singlet oxygen, ozone, and hypochlorous acid [18]. Some of these free radicals are described in more detail below.

The superoxide radical exists in two forms such as superoxide or hydroperoxyl radical anion [18]. The enzymes that can produce superoxide include xanthine oxidase [63], lipoxygenase, cyclooxygenase [9, 21], and nicotinamide adenine dinucleotide phosphate- (NADPH-) dependent oxidase [30].

Hydrogen peroxide is formed by the enzyme superoxide dismutase (SOD). It can easily penetrate the biological membranes and damage DNA by producing the hydroxyl radical [29]. The hydroxyl radical can strongly react with both organic and inorganic molecules [17].

Nitric oxide is generated by different nitric oxide synthases (NOSs). Three types of NOS isoforms are distinguished, that is, neuronal NOS (nNOS), endothelial NOS (eNOS), and inducible NOS (iNOS). Nitric oxide is an important intracellular second messenger [18]. It is involved in a number of biological functions such as blood pressure regulation, smooth muscle relaxation, neurotransmission, defense mechanisms, and immune regulation [11].

Peroxynitrite, which is highly toxic, is formed by the reaction between the superoxide radical and NO (nitrogen monoxide) [61]. During the subsequent reaction, new reactive compounds lead to oxidation processes of lipids, proteins (methionine and tyrosine), and DNA [24].

2.2. Redox Processes in MS

Researchers suggest that dysregulation of axonal bioenergetics plays a critical role in OS and subsequent axonal injury [25, 64].

Interestingly, the examination of the cerebrospinal fluid (CSF) during exacerbation of MS revealed a bioenergetic failure that was associated with an increased mitochondrial proton leak and an increased expression of genes involved in oxidative damage [3537]. Moreover, the presence of proinflammatory cytokines in the CSF and prooxidative markers (e.g., nitrotyrosine) led to cytokine-induced synaptic hyperexcitability and consequent glutamate-dependent neurotoxicity [34, 40].

Recent studies suggest the importance of ceramides in the CSF as signaling molecules leading to impaired mitochondrial function. The short-chain ceramides stimulated oxygen species production and led to neuronal death [23, 39].

Iron accumulation in the brain is of great importance. This process leads to chronic cell stress, resulting in axonal and neuronal death [70]. Abnormal iron accumulation was found in MS plaques. Extracellular hemoglobin oxidized and led to local OS through the globin radical which was responsible for myelin basic protein oxidative cross-linking and heme involved in lipid peroxidation [70].

The process of neurodegeneration depends on the liberation of iron from the myelin sheath during demyelination [22]. A diffuse neurodegenerative process is related to the high iron content in the basal ganglia [20]. Ferrous iron may strengthen oxidative injury in the presence of oxygen radicals produced by the oxidative burst [16, 26, 33]. Oxidative stress, mitochondrial injury, and energy failure may be involved in plaque formation and neurodegeneration in white and grey matter lesions [41, 56, 71]. Another scientific report suggested that neurodegeneration in MS was associated with chronic subclinical extravasation of hemoglobin into lesions, the dysfunction of different cellular protective mechanisms against extracellular hemoglobin reactivity and OS [57].

Other studies stressed that alterations in the oxidant/antioxidant balance contributed to the pathophysiology of MS. Consideration was given to the balance between the concentration of compounds such as lipid peroxidation levels, carbonyl protein content, DNA damage and SOD, CAT activities, vitamins C and E, and nonprotein thiol content [42]. Also, the presence of free radicals in the nervous tissue may be toxic; for example, peroxynitrite increases inflammation and in the chronic phase leads to such a high concentration that it may lead to neurodegeneration [13].

Due to a constant lack of useful markers of the disease, it is important to find compounds whose levels are easy to mark, which may bring vast clinical implications. The review of the literature presented below is an attempt to collect biomarkers.

2.3. Markers of OS for Assessment: Serum, Erythrocytes, CSF, Saliva, Urine

Free radicals can damage biological molecules including nucleic acids, proteins, and lipids [18, 66]. The products of these reactions can become markers of OS. Serum is the most common material for the evaluation of the components of OS. It allows the estimation of most enzymes, substrates, and products of redox reactions. These enzymes include xanthine oxidase, NOS, lipoxygenase, cyclooxygenase, myeloperoxidase [47], prolyl oligopeptidase [51], nicotinamide adenine dinucleotide phosphate-oxidase 1 (NOX1), and NADPH-dependent oxidase [30]. The following may become the markers of oxidative lipid damage: isoprostanes (IsoP-prostaglandin like substances), for example, 8-iso-prostaglandin (F2α-8-iso-PGF2α) which constitutes the product of lipid peroxidation of arachidonic acid, malondialdehyde (MDA) [18], the formation of fluorescent peroxidized lipid-protein covalent adducts, and the increase in conjugated diene [70]. Oxidative stress involves the oxidation of proteins and glycoxidation. The following are the results of this reaction: the glycophore content, the total level of advanced protein oxidation (AOPP), protein carbonyls, dityrosine level, N′-formylkynurenine, and a decreased level of serum protein thiol groups [55].

The other specific markers of protein oxidation such as tyrosine (a marker for hydroxyl radical) and 3-nitrotyrosine (a marker for RNS) [43] are also considered. Furthermore, 3-nitrotyrosine is a specific marker of peroxynitrite-induced cellular damage [18].

Another study showed a possibility of using parameters such as ketodienes and Schiff bases [46]. Other indicators in the serum included kynurenine, N′-formylkynurenine, thioredoxin [32], and 8-hydroxy-2′-deoxyguanosine [47].

The parameters used for the measurement of the overall level of OS among healthy individuals and patients with MS are as follows: the total oxidant status (TOS), the oxidative stress index (OSI), and the total antioxidant status (TAS). This reflects the overall level of OS. In turn, OSI is defined as the ratio of TOS to TAS. The total antioxidant status shows the overall level of antioxidant capacity of the human body [72]. The oxidative stress index determines the oxidant/antioxidant balance more reliably in the body.

Following further research, more mediators may be determined in the serum, such as thiobarbituric acid reactive substances, advanced oxidation protein products, fructosamine [73], and activated α-2-macroglobulin level [51]. Both AOPP and MDA may be also marked in erythrocytes [74, 75]. Furthermore, the following are also measured in the CSF: levels of MDA and IsoP [54, 76, 77], ceramides [78], chemokine 11 (CCL11) [79], AOPP, and a decreased level of total thiol groups [80].

Both saliva and urine may serve as a useful material. The levels of thiobarbituric acid reactive substances and advanced glycation end-products can be assessed in saliva [73]. Urine may be a good material for the assessment of urinary 8-iso-PGF2α, which is a marker of lipid peroxidation in vivo [81].

Researchers reported that acrolein (2-propenal) might strengthen OS [59]. Acrolein antibody strategy was indicated to measure local acrolein levels but quantification of urinary 3-hydroxypropylmercapturic acid (3-HPMA) was the best marker for measuring global acrolein accumulation when glutathione levels were not depleted [82].

Other biomarkers are serum levels of IL-6, tumor necrosis factor (TNF-α), interferon γ (IFN-γ), IL-4, IL-10, and IL-17, albumin, ferritin, plasma levels of lipid hydroperoxides (CL-LOOH), carbonyl protein, and nitric oxide metabolites (NOx) [83]. Lipophilic fluorescent end-CL-products of free radicals may be an interesting marker [84]. Oxidative stress is also evaluated by tert-butyl hydroperoxide-initiated chemiluminescence [85] or the formation of ROS from 2′,7′-dichlorodihydrofluorescein-diacetate fluorescence [86].

The oxidative stress factors possible for assessment in serum, erythrocytes, CSF, saliva, and urine are collectively presented in Table 1.

Table 1: Biomarkers of oxidative stress. Free radicals can damage biological molecules including nucleic acids, proteins, carbohydrates, and lipids with the participation of various enzymes. As a result of these reactions new compounds are formed which may become biomarkers. Most of the available biological materials can be used to measure the level of these compounds in MS patients.
2.4. Linking OS Markers with Disease Course, Relapses, Disability, and MRI Lesions

A number of researchers try to find OS markers which are connected with MS. The review of the literature shows that there are some OS markers of the disease course; for example, studies demonstrated a significant increase in the levels of 8-iso-PGF2α in the CSF of patients with SPMS [86]. Guan et al. showed high levels of urinary 8-iso-PGF2α (a marker of lipid peroxidation in vivo) in MS patients. The concentration of urinary 8-iso-PGF2α was significantly higher in patients with SPMS and PPMS as compared to the control group [81]. It was also shown that a reduced level of prolyl oligopeptidase activity and activated α-2-macroglobulin level in the plasma were characteristic of PPMS and RRMS [51]. In addition, in another study plasmatic AOPPs were equally higher in RRMS and SPMS patients [87].

Recently acrolein, an endogenously produced toxic compound and a pathological factor in MS, underwent analysis [88]. It may be used as a potential biomarker for diagnosis and prognosis of MS [82].

Results from the study of Fiorini et al. showed that proteins such as hemopexin, alpha-1-B glycoprotein, inter-a-trypsin inhibitor heavy chain H4, complement C3, and antithrombin III were found to be more oxidized in pathological samples. Oxidation of these proteins might be used to determine the level of OS in the body [1].

Recent scientific findings, which offer the first evidence of increased RNA oxidation in normal-appearing cortex of MS brain, seem to be of great importance. However, further studies are needed to clarify the role of RNA oxidation in MS brain [89].

Cerebrospinal fluid IsoP, which is an OS marker of relapse, was higher in patients with a first clinical attack suggestive of MS as compared to the controls [77]. In turn, lower vitamin D levels may be responsible for the development of MS [42]. It may be related to vitamin D-binding protein (DBP) which was found to be more oxidized in both remitting and relapsing phases. However, higher levels of oxidation rate of DBP were observed during relapses. The increased oxidation rate of DBP already observed in the remitting course showed that some molecular pathways were not completely suppressed during remission as compared to the controls [1].

The degree of oxidation of clusterin was upregulated in MS patients as compared to the healthy controls [1]. This protein was responsible for chaperone-activity already increased in the remitting phase and kept upregulated in the relapsing phase [1].

Karlík et al. reported higher levels of thiobarbituric acid reactive substances and advanced glycation end-products in the saliva of patients with relapse. The study also demonstrated an increase in other OS markers of relapses in the plasma such as thiobarbituric acid reactive substances, advanced oxidation protein products, and fructosamine [73].

Oxidative stress markers of disability included platelet hemostatic function which was advanced in SPMS patients and positively correlated with an increased production of the superoxide radical and with the Expanded Disability Status Scale (EDSS). It seems that the platelet function is activated by a high level of OS [90].

Furthermore, in one of the studies it was demonstrated that inflammation, oxidative and nitrosative stress biomarkers such as serum levels of IL-6, TNF-α, IFN-γ, IL-4, IL-10, and IL-17, albumin, ferritin, and plasma levels of CL-LOOH, carbonyl protein, AOPPs, NOx, TRAP, and NcoI TNFβ genotypes might be considered potential predictive biomarkers of high disability in MS (EDSS) and were associated with different aspects of disease progression (higher pyramidal symptoms, sensitive symptoms, and cerebellar symptoms) [83].

Another study, including 110 patients with MS, demonstrated that patients with insulin resistance (IR) had a higher level of disability (EDSS), higher levels of interleukin IL-6 and IL-17 and OS evaluated by tert-butyl hydroperoxide-initiated chemiluminescence and AOPPs compared to patients without IR. It appears that IR and adiposity could contribute to more OS and disability [85].

Other studies indicated that the EDSS and gadolinium enhancement lesion volume-Gd+ were affected by increased levels of OS in erythrocytes in CIS, RRMS, and SPMS patients (increased level of AOPP and MDA) [74, 75].

Summarizing the above observations, the following may become OS markers of disability (EDSS): advanced platelet hemostatic function and increased level of AOOPs and MDA in erythrocytes and plasma levels of CL-LOOH, carbonyl protein, AOPPs, NOx, and TRAP. Additionally, IL-6, IL-17, TNF-α, IFN-γ, IL-4, IL-10, IL-17, and OS were evaluated by tert-butyl hydroperoxide-initiated chemiluminescence.

Data on OS and MRI lesions reported that a higher level of AOPP and a decreased level of total thiol groups in the plasma and in the CSF were involved in the clinically isolated syndrome (CIS) and RRMS pathophysiology but not with total T2 weighted lesions number and Gd enhancement lesion volume [80].

3. The Importance of Antioxidants in MS

Oxidative stress at each stage of MS is a key element in the pathogenesis of the disease. At the time of relapse all these processes are intensified, leading to the loss of neurons over years. Current treatment is focused on decreasing inflammation, however only partially on preventing neurodegeneration. It is possible that a new target of treatment will focus on neutralizing free radicals. The course of the disease is affected by the use of antioxidants and substances that affect antioxidant pathways which reduce the severity and cause faster remission and less pronounced course of neuroinflammation and neurodegeneration [76, 91].

The following is a short description of antioxidants and their practical application in MS.

3.1. Enzymatic and Nonenzymatic Antioxidants

Antioxidants, which are divided into enzymatic and nonenzymatic, are substances that protect the body against free radicals (Table 2). Among enzymes the most important include catalase (CAT), glutathione peroxidase (GPx), glutathione reductase (GR), superoxide dismutase (SOD), serum paraoxonase, arylesterase [45], and δ-aminolevulinate dehydratase (δ-ALA-D) activity [42]. Superoxide dismutase has three isoforms that is, copper/zinc SOD (SOD-1), manganese SOD (SOD-2), and extracellular EC-SOD [13]. It needs to be stressed that in the serum the major antioxidant enzymes include CAT, GPx, peroxiredoxins [18, 92, 93], glutathione-S-transferases (GSTs), and nitrite reductase NAD(P)H quinone oxidoreductase 1 (NQO1) [38]. The concentration of these enzymes in the serum may reflect the status of an antioxidant line of defense.

Table 2: The types of antioxidants. The types of antioxidants depend on molecular structure. The table lists the most important barrier antioxidant enzymes and other compounds and ions which are not enzymes.

Nonenzymatic antioxidants may be classified into low molecular weight and antioxidant elements (ions). Low molecular weight antioxidants include uric acid (UA), vitamins C, D, and E, glutathione, coenzyme Q, and b-carotene [13]. Iron (Fe), copper (Cu), zinc (Zn), and manganese (Mn) are the most important ions with antioxidant properties. The general and nonprotein thiol groups represent a nonenzymatic segment of the antioxidant defense system [46].

3.2. Antioxidant Factors Possible for Assessment: Serum, Erythrocytes, CSF, Saliva, and Urine

The following can be assessed in the serum: UA [13], nonprotein thiol groups [42, 46], and the total glutathione and reduced glutathione [47]. The lowest molecular weight antioxidants can be used. Other markers of antioxidant ability in the body may be determined in the CSF, for example, concentration of Klotho (an antiaging protein) [94] and total thiol groups [80]. Uric acid may be determined in the CSF; however its concentration depends on the leakage of UA molecules from the serum through the blood-brain-barrier (BBB) and the balance between consumption and production within the CNS [27].

Furthermore, an impaired iron metabolism plays a major role in the pathogenesis of MS [18]. One of a few studies reported that in the saliva of patients with MS ferric reducing ability (FRA) was decreased by 38% as compared to the controls [73]. Ferroxidase (FeOx) activity of ceruloplasmin prevents OS by promoting the connection of free radicals from iron ions to transferrin. A reduced serum FeOx activity was noted in 69 RRMS patients and in 62 patients with other inflammatory neurological disorders [95]. To summarize, FRA can be measured in saliva [73] whereas the ferroxidase (FeOx) activity may be determined in the serum [95].

Erythrocyte SOD and GPx can be marked in erythrocytes [74]. Urine assessment is a noninvasive method useful in the measurement of the oxidative status. Gholipour et al. showed that urine 6-sulphatoxymelatonin (aMT6s, major metabolite of melatonin) levels were significantly lower in MS patients as compared to the control group [96].

Two parameters appear to be significant, that is, the total radical-trapping antioxidant parameter (TRAP) and the total antioxidant status (TAS). The first parameter may be measured by a fluorescence-based method (TRAPm) or calculated (TRAPc) by a mathematical formula, considering antioxidant levels in the serum, that is, protein-bound thiol groups, UA, and vitamins E and C [97]. What is important, TRAP was recently proposed to measure the antioxidant level in the plasma [83]. The difference between TRAPm and TRAPc is due to antioxidants, which are still unidentified [97]. Furthermore, TAS can be determined in the serum and it reflects the overall level of antioxidant capacity of the patient [45].

The antioxidant factors possible for assessment in serum, erythrocytes, CSF, saliva, and urine are collectively presented in Table 3.

Table 3: The Biomarkers of antioxidant capacity. The serum is assayed for enzymes with antioxidant properties. There are also other compounds and important parameters which can be assessed in the serum. In addition, new possibilities for the use of other biological materials occurred. All these markers provide knowledge about the antioxidant status of the organism.
3.3. The Impact of External and Internal Antioxidant Factors on the Course of Disease, Disability, and MRI Lesions

It was reported that melatonin (10 mg daily/30 days) caused a statistically significant increase in antioxidative enzymes such as SOD and GPx and a decrease in MDA in erythrocytes of SPMS patients [74]. This suggests the possibility of a positive impact of melatonin on the course of severe forms of MS. Glutathione is an antioxidant in the brain which might be a marker of the oxidative line of defense in MS patients and also might serve to monitor the disease course [31].

Another study showed that an expression of antioxidant power such as plasmatic ferric reducing ability (FRA) and thiol group dosage were significantly lower in patients with active disease [87], which may worsen the prognosis. Interestingly, the GSTP1 polymorphism and quinone oxidoreductase 1 (NQO1) variant genotypes in MS patients suggested that a defective function of detoxification enzymes might be a determinant of susceptibility and the clinical manifestation of the disease [38].

One of the studies examined coenzyme Q10 and antioxidized low-density lipoproteins (anti-oxLDL) antibodies, which may help to maintain the BBB integrity and might result in a mild disease course [98].

Aleagha et al. indicated that a decreased concentration of Klotho in the CSF of patients with RRMS showed a significant negative correlation with the disability [94]. Recent reports indicated that decreased urine aMT6s levels significantly correlated with the MS Functional Composite Score. The authors believe that there might be some new hope in developing a quantitative and objective measure to assess the severity of MS [96]. The urine aMT6s levels were not correlated with the level of disability measured by the EDSS scale [96].

Serum UA concentrations in 30 MS patients and 20 controls with noninflammatory neurological diseases supported the significance of UA in the pathogenesis of MS. Serum UA concentrations were found to be significantly lower in MS patients as compared to the controls [27]. However, CSF UA concentrations might not be a reliable marker of disease activity in MS which was assessed by MRI lesions and the CSF/serum albumin quotient [27].

On the other hand, the relationship between disability, MRI Gd + lesions and SOD concentration in erythrocytes in CIS and RRMS patients is not clear and requires further studies [74, 75].

3.4. Opportunities for Antioxidant Supplementation in MS: What Can Be Supplemented?

Neuroprotection seems to be a vast area to explore, common to a number of neurodegenerative diseases, including MS. The role of OS in MS appears to be vital. Currently, a large therapeutic potential lies in antioxidants. Research focuses on finding new substances with antioxidant properties.

The melatonin supplementation appears to be useful [74, 75, 99] and may scavenge the hydroxyl, carbonate, alkoxyl, peroxyl, and aryl cation radicals and stimulate the activities of antioxidative enzymes (GPx, SOD, etc.) [74]. It was confirmed that melatonin also plays an important role in improving the antioxidant defense in MS through upregulation of sirtuin 1 (SIRT1) and its target genes for MnSOD and CAT [100]. Moreover, melatonin is selectively taken up by mitochondrial membranes, which makes it a potential therapeutic tool in treating neurodegenerative disorders [50].

In vitro studies demonstrated that dihydroasparagusic acid prevented lipopolysaccharide-induced production of neurotoxic mediators such as NO, TNF-α, prostaglandin E2, inducible NOS, cyclooxygenase-2 protein expression, and lipoxygenase activity in microglial cells [101].

Oxidative stress is also responsible for depletion of n-3 polyunsaturated fatty acid (PUFA), leading to disruptions in the lipid-based signaling, intracellular signal dysfunction and increased neurotoxicity. Consequently, n-3 PUFA supplementation is a rational therapeutic approach [102].

α- (alpha-) Lipoic acid (ALA) is a natural, endogenous antioxidant that acts as a peroxisome-proliferator-activated receptor-γ (PPAR-γ) [49]. The researchers showed that increased δ-ALA-D activity may be a protective agent against OS [42]. The data provided the first evidence that ALA might increase the production of PPAR-γ in vivo in experimental autoimmune encephalomyelitis (EAE) and might reveal antioxidative and immunomodulatory mechanisms for the application of ALA in human MS [49]. Khalili et al. suggested that 1200 mg of lipoic acid daily improved serum TAC among RRMS patients without affecting other biomarkers [103]. On the other hand, one of the systematic reviews showed that over-the-counter antioxidants such as epigallocatechin-3-gallate and ALA offered benefits, however only in preclinical studies. There is no evidence that they alter MS relapses or the disease progression [14].

Interestingly, a randomized study conducted on a sample of 24 patients with RRMS proved that supplementation of coenzyme Q10 for 12 weeks resulted in an increase SOD activity, plasma TAC, and a decrease in MDA levels as compared to the controls [104].

Idebenone, an organic compound known as a synthetic analog of coenzyme Q10, was proven to be beneficial in Friedreich’s ataxia and Leber’s hereditary optic neuropathy. In these diseases idebenone protected neuronal HT22 cells from glutamate-induced death in vitro. Fiebiger et al. reported that the histopathological examination of the CNS of idebenone-treated mice showed no improvement in inflammation, demyelination, or axonal damage. It seems that this is not a preferred method of MS treatment [105].

It was also shown that serum lipophilic antioxidants, that is, γ-tocopherol, β-carotene, and coenzyme Q10 were deficient or moved within the border of lower physiological value in a vast majority of MS patients. Researchers suggested that the deficit of lipophilic antioxidants in the blood of MS patients could have a negative impact on bioenergetics of reparative demyelinating processes and could promote neurodegeneration [25].

3.5. Antioxidants of Plant Origin

Ghaffari et al. reported that treatment with two doses of saffron extract (5 and 10 μg/rat) weekly resulted in a growth of total antioxidant reactivity capacity, lipid peroxidation products, and antioxidant enzymes activity in the hippocampus of experimental models of MS compared to the controls [106]. Other studies demonstrated that the administration of Nigella sativa seeds in EAE induced in Wistar rats suppressed inflammation, enhanced remyelination in the cerebellum, and reduced the expression of transforming growth factor beta 1 (TGF β1) [107]. In turn, a nanodroplet formulation of pomegranate seed oil (denominated nano-PSO) dramatically reduced oxidation of lipids in the brains of rats [48, 108].

A small number of MS patients () demonstrated a protective effect of hypericum perforatum, which resulted in an increase in neutrophil GPx activity and a decrease in intracellular free calcium ions [109]. Some studies indicated that a low fat diet and antioxidant supplements could reduce levels of free radicals [110112]. Dietary flavonoids have a potential to protect neurons against OS, an ability to suppress neuroinflammation and modulate cell signaling pathways [112]. Flavonoids such as luteolin, quercetin, and fisetin at concentrations of 20–80 μM decrease the amount of myelin phagocytosed by macrophages [113].

Other studies described a number of potential antioxidants, such as cerium oxide nanoparticles, and sulforaphane, which is an organosulfur compound present in vegetables, ginseng, hemp seed, and evening primrose oils [114116]. Matrine (MAT) is another antioxidant of plant origin. It is a quinolizidine alkaloid derived from the herb Radix Sophorae Flave. In EAE MAT treatment significantly upregulated the expression of the transcription factor such as nuclear factor (erythroid-derived 2) like 2 (Nrf2) which plays a role in inhibiting OS [58].

Following further studies, synthetic inhibitors of phospholipase A2 (PLA2) from plants including curcumin, ginkgo biloba, and Centella asiatica extracts were also used for the treatment of neurological disorders [108].

4. Inflammatory Mediators and Antioxidants

New findings suggest that chemokine 11 (CCL11) in the serum and in the CSF released from activated astrocytes promoted OS via microglial NOX1 activation and glutamate-mediated neurotoxicity. These findings proposed using inhibitor of NOX1 in therapy [79]. Another study explained how TNF-α inhibited the differentiation of progenitor cells. The effect depended on a number of factors such as increased ROS production, altered mitochondrial calcium uptake, mitochondrial membrane potential, and respiratory complex I activity. The accumulation of progenitor cells at the lesion sites was observed in MS patients [117] and suggested that failed remyelination was a consequence of the inhibition of differentiation [118120]. In another study, authors presented the possibility of using a TNFR2 agonist as a factor protecting oligodendrocyte progenitor against OS [121].

Scientists suggested that enhanced astrocytic peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) levels reduced the production of proinflammatory mediators such as IL-6 and chemokine (C-C motif) ligand 2 and increased the expression of antioxidant enzymes, including peroxiredoxin-3 and thioredoxin-2 in generated human primary astrocytes. Activation of PGC-1α may be a protective factor for neurons [44].

The results from the study of EL Andaloussi et al. presented the use of exosomes, biologically active nanovesicles (30–120 nm) that could be easily delivered across the BBB [122] as an improvement to induce postinjury remyelination processes. They stimulated primary dendritic cells cultures with low-level IFNγ. Exosomes (IFNγ-DC-Exos) contain microRNA species which are involved in oligodendrocyte development pathways and can increase baseline myelination, reduce OS, and improve remyelination. Researchers also found that IFNγ-DC-Exos increased oxidative tolerance and antioxidant levels in microglia and potentially included anti-inflammatory miRNAs. Furthermore, IFNγ-DC-Exos nasally administered to animals increased CNS myelination in vivo [123].

5. The New Possibilities in the Treatment of MS: Neuroprotection

A number of substances are tested for a possible ability to protect the brain against neurodegeneration. In addition, the development of neuroprotective drugs is more problematic [6]. A limited response to the application of ROS scavengers results from their short half-life, on the order of milliseconds and the degree of instability of ROS [3, 59, 124, 125].

Hydralazine may become a potential target for therapy due to the fact that it protects cells from the damaging effects of acrolein [59, 126128].

Novel agents/approaches could offer help in preventing mitochondrial dysfunction and in improving neurodegeneration. The following are considered: CDDO-ethyl amide, CDDO-trifluroethylamide, pioglitazone, rosiglitazone, resveratrol, 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR), and bezafibrate [129].

Other findings suggested that neural stem cells (NSCs) exposed to 125 μM H2O2 for 30 min and pretreated with different doses of lovastatin for 48 h were protected against OS-induced cell death by the expression of PGC-1α, which is a master regulator of mitochondrial function controlling energy metabolism and Nrf2. It is possible that in the future lovastatin may be used to promote the survival rate of NSCs [130]. The former group which can readily cross the BBB includes simvastatin, atorvastatin, and cerivastatin while hydrophilic statins include rosuvastatin and pravastatin [131].

The experimental results of the effects of exendin-4 and glucagon-like peptide-1 (GLP-1) in several mouse models of MS were reported by Hölscher. The main inflammatory responses were much reduced, as well as the intensity of demyelination. The cytokine release in the spleen was also reduced. It was shown that most GLP-1 mimetics such as exendin-4, liraglutide, and lixisenatide crossed the BBB and showed neuroprotective effects [132, 133]. However, further studies are needed to clarify the relationship with OS.

Novel treatments can be rated in EAE, a mouse model of MS. One of the scientific reports showed the effect of polymerized form of nanocurcumin (PAP) on EAE, which might have a therapeutic effect as an anti-inflammatory and antioxidative stress agent with significant effects on myelin repair mechanisms [133]. Using nontoxic inhibition of myeloperoxidase might restore the BBB integrity thereby limiting migration of myeloid cells into the CNS that drive EAE pathogenesis. These inhibitors may be an effective therapeutic agent for the treatment of MS [134]. Yun et al. discovered a new molecule with a neuroprotective activity, that is, antioxidant protein peroxiredoxin 6 (PRDX6), which can reduce the inflammation in the CNS and potentiate oligodendrocyte survival [135]. The modulation of glutamate release and transport may also become a new therapeutic target [136].

The process, known as “remote damage” may have a significant effect on neurodegeneration. This process can damage neurons functionally related to the primary focus for months and years after the original damage such as stroke, multiple sclerosis, amyotrophic lateral sclerosis, and traumatic injury to the brain and the spinal cord. “Remote damage” may be defined as a variety of pathological processes, such as apoptosis, inflammation, glial activation, oxidative damage, neuronal changes in receptor mosaics, and autophagy. The impact of these factors is important at different times. Viscomi et al. attempted to investigate this process using the hemicerebellectomy (HCB) experimental paradigm. The researchers presented the idea of new therapies based on blocking “remote damage.” The therapeutic window that occurs between the primary and secondary damage can be used to implement new neuroprotective treatment [137139].

As it can be seen, not all the studies on the role of antioxidants in MS are consistent and further research should be done to test new substances for their effectiveness.

6. The Relationship between Immunomodulatory Therapy, OS, and Antioxidants

Immunomodulatory therapies are used to protect from relapses whereas corticosteroids are commonly used in the acute treatment of relapses.

The relationship between OS and dimethyl fumarate (DMF) is partially explained. The transcription factor (Nrf2) is a key regulator of antioxidative defense. Oral DMF activates anti-inflammatory and antioxidative pathways to upregulate the expression of this molecule [15, 52, 140]. A differential expression is involved in the defense against OS, predominantly in actively demyelinating white matter lesions [140142]. Treatment of oligodendrocytes with DMF induces changes in citric acid cycle intermediates, glutathione, and lipids, indicating that this compound can protect oligodendrocyte metabolism and provide protection from OS [140].

Dimethyl fumarate and monomethyl fumarate (MMF), the immediate metabolite of DMF, activate Nrf2 transcriptional pathways. Target genes of Nrf2 include glutamate cysteine ligase transcription factor 1 and NAD(P)H oxidoreductase-1, resulting in cytoprotective effects against oxidative cellular injury. It is a potential novel mode of action differentiating this drug from other immune-modifying drugs [143]. This mechanism explains the possibility of using this drug in other degenerative diseases of the CNS, such as Parkinson’s disease [144]. It is possible that dimethyl fumarate activates the prostaglandin EP2 receptor and consequently inhibits the progression of MS via the cAMP signaling pathway. This is another recently discovered mechanism of action which needs to be clarified due to OS in MS [145]. Dimethyl fumarate attenuates overproduction of ROS, which results in a decrease in a lipid peroxidation product, 7-ketocholesterol induced by ROS. It can protect murine oligodendrocytes 158N (myelin synthesizing cells) against apoptosis and autophagy. It may be responsible for neuroprotection [53]. Another effect of DMF may be associated with the activation of heme oxygenase-1 [146]. The use of a signaling pathway of the Kelch-like ECH-associated protein 1-nuclear factor erythroid 2-related factor 2-antioxidant-responsive element (Keap1-Nrf2-ARE) in vivo and in vitro leads to the downregulation of OS and inflammation, activated by DMF which may protect the nervous tissue against subarachnoid hemorrhage induced brain injury in rats [147]. In addition, it is suspected that DMF could strengthen the BBB by targeting interendothelial junctions in an Nrf2-dependent manner, thus protecting against cerebral edema during ischemic stroke [148]. On the other hand, in one of the studies on the Nrf2 pathway DMF enhanced the severity of lung carcinogenesis in mice [149].

It was also shown that therapies aiming at stimulating endogenous antioxidant pathway, for example, by inducing the Nrf2 pathway [65], may be quite effective in a situation of moderate OS such as the one in classical EAE models. However, they might be ineffective or even counterproductive in the case of extensive oxidative injury. It was proposed that the amplification of oxidative injury in MS was only reflected to a limited degree in the studied rodent models [150].

A new study reported that treatment with fingolimod reduced hyperoxia-induced OS, activation of microglia, and associated proinflammatory cytokine expression in neonatal oxygen-induced brain injury. The thesis could in part explain the efficacy of fingolimod in MS, in which OS plays an essential role [151].

IFNγ can damage myelin by spreading depression as in migraine with aura. In contrast, the physiological level of IFNγ as produced by environmental enrichment protected against demyelination and OS and was associated with a moderate and phasic increase in a number of proinflammatory cytokines. The controlled administration of pulsed IFNγ to brain slice cultures imitating environmental enrichment reduced OS, increased the concentration of myelin basic protein, and reduced spreading depression. Furthermore, stimulation of brain slice cultures with IFNγ induced the release of exosomes that had most likely neuroprotective functions [152].

Some studies attempted to prove the efficacy of IFN-β which was connected with other immunomodulatory therapies or antioxidant therapies. For instance, it was reported that treatment with IFN-β and glatiramer acetate significantly reduced TNF-α. However, it did not affect other ROS/NRS biomarkers or disease progression [83].

In another study the level of protein carbonyls was elevated in RRMS patients treated with interferon β-1b and glatiramer acetate, whereas the serum protein thiol groups were decreased. Following the same study in RRMS patients without immunomodulatory therapy the same markers of OS were significantly elevated [55]. Sadowska-Bartosz et al. demonstrated an increase in oxidation parameters in the serum in RRMS patients treated with interferon β-1a and interferon β-1b. However, this increase was less significant compared to untreated RRMS patients or SPMS patients treated with mitoxantrone [32].

Treatment with the combination of glatiramer acetate and N-acetylcysteine had a favorable safety profile. Moreover, it had a positive effect on the redox state [153]. The administration of glatiramer acetate to female BALB/c mice under stress conditions resulted in normalization of ROS levels, restored nNOS activity, and resulted in clinical improvement in learning [154].

Another study demonstrated that melatonin supplementation at a dose of 5 mg over 90 days resulted in a significantly decreased MDA concentration in INF-β and glatiramer acetate-treated groups, however not in the mitoxantrone-treated group. In turn, a significant increase in SOD activity was observed only in glatiramer acetate-treated group as compared to the controls [155]. Interestingly, melatonin may also have implications for the treatment of severe MS. One of the studies indicated that the TAC level was significantly lower in the mitoxantrone-treated group and it increased after melatonin supplementation [156].

Using C-phycocyanin, a biliprotein from Spirulina platensis with antioxidant, anti-inflammatory, and cytoprotective properties and INF-β improved the redox status in mice with EAE, although they also differentially modulated another subset of genes. C-phycocyanin mainly modulated the expression of genes related to remyelination, gliogenesis, and axon-glia processes, which may be significant in neuroregeneration [157]. Therefore, a combined use of immunomodulatory therapies with antioxidants may prove beneficial.

Attempts were also made to explain some of the beneficial effects of natalizumab and its antioxidant capacity. Researchers studied serum melatonin levels in 18 patients with RRMS treated with natalizumab and noted that it caused significant increases in serum melatonin concentrations [158]. In one of the studies 22 MS patients were assigned to the treatment with 300 mg of natalizumab. After 14 months it was observed that natalizumab prompted a decrease in oxidative-damage biomarker levels, induced nuclear translocation of Nrf2 which was responsible for the activation of the antioxidant pathway, and a fall in serum vascular cell adhesion molecule-1 levels [47]. In addition, it was found that a decrease in carbonylated protein levels was connected with the patients with the highest levels of severity in the process (EDSS > 5) and treatment with natalizumab [159]. Consequently, it resulted in an increase of antioxidants and a reduction in OS biomarkers.

It should be borne in mind that mitoxantrone is potentially associated with an increased level of OS but on the other hand, the study demonstrated that mitoxantrone did not have an effect on the activity of paraoxonase 1 (an enzyme that protects the cell from OS) [160].

Arnold et al. evaluated the suicidal erythrocyte death induced by mitoxantrone. The study proved that mitoxantrone triggered cell apoptosis, partially due to the formation of ROS and ceramide thus increasing OS. Additionally, the authors assessed the effect of adding the antioxidant N-acetylcysteine, which significantly reduced the effect of mitoxantrone [86].

Due to the fact that the studies were not conclusive, it appears that treatment with interferon and mitoxantrone does not reduce OS [32].

To conclude, it appears that most of the drugs used in MS are directly or indirectly associated with OS.

7. Corticosteroids in Relapses: The Importance of OS and Antioxidants

The role of corticosteroids in OS is poorly understood. Wang et al. examined levels of MDA and TAC in peripheral blood and the CSF of RRMS patients in 7 days before methylprednisolone (MP) treatment and one month after MP treatment. They found that the increase in OS markers preceded inflammatory response in MS patients and MP treatment reduced the neuroinflammatory attack by decreasing brain antioxidant enzymes [54].

Ozone autohemotherapy is an emerging therapeutic technique that can change the brain metabolism. It was recently shown that MS patients demonstrated a marked increase in cytochrome-c-oxidase (CYT-c) activity and concentration about 40 minutes after the end of the autohemotherapy, possibly revealing a reduction of the chronic OS level typical of MS sufferers [161].

A protective effect of ozone (O3) therapy was reported in EAE in rats either alone or in combination with corticosteroids. Such a combination allowed reducing the dose of MP due to a decreased level of brain glutathione, paraoxonase 1 enzyme activity, brain MDA, TNF-α, IL-1β, IFN-γ, Cox-2 immunoreactivity, and p53 proteins [162]. The study showed that adding compounds that modulate redox pathways in the cell could increase the effectiveness of the therapy and reduce a dose of corticosteroids.

8. Conclusions

The brain tissue, with a considerable number of phospholipid membranes, is very sensitive to the action of radicals due to a significant presence of mitochondria and consequently massive oxygen metabolic processes. A number of studies document the participation of OS in MS pathophysiology. Oxidative stress processes participate in both inflammatory and neurodegenerative pathophysiological components of MS. Oxidative stress is associated with the dysregulation of axonal bioenergetics, cytokine-induced synaptic hyperexcitability, abnormal iron accumulation, and the oxidant/antioxidant balance. Markers of OS assessed in the serum, erythrocytes, CSF, saliva, and urine may have diagnostic properties whereas antioxidants may have clinical application in the future. There are at least a couple of OS markers of the disease course which can be particularly useful in the diagnosis of severe forms of MS such as SPMS and PPMS. Other useful applications include markers of relapse and OS markers of disability. There might be some new hope in an objective assessment of the severity of MS.

Many antioxidants may have a positive impact on the course of MS. These substances include melatonin, dihydroasparagusic acid, n-3 polyunsaturated fatty acid (PUFA), α- (alpha-) lipoic acid (ALA) and others (including plant origin antioxidants). Innovative therapies are aimed in particular at neuroprotection and neurodegeneration. Potential drugs include compounds such as hydralazine, exendin-4, glucagon-like peptide-1 (GLP-1), and also lovastatin which protects against OS-induced cell death by the expression of PGC-1α and Nrf2.

Currently, a number of new studies focus on the immunotherapy and OS. Natalizumab and fingolimod have a positive effect on antioxidant capacity and may result in a reduction in OS markers. The relationship between DMF and OS is best known and is associated with the modulation of OS molecules. On the other hand, mitoxantrone is a drug that may be responsible for an increase in OS. There are new suggestions combining mitoxantrone therapy with antioxidant supplementation such as N-acetylcysteine and melatonin in order to alleviate the toxicity of mitoxantrone.

Summarizing, using OS markers as biomarkers of MS severity or relapse could be a long-awaited helpful diagnostic tool. Moreover, adding antioxidants to immunotherapy which is well-established in MS may be reasonable and highly beneficial for MS patients due to their ability to reduce OS. Further research should be done to test new antioxidants for their effectiveness.

Competing Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

References

  1. A. Fiorini, T. Koudriavtseva, E. Bucaj et al., “Involvement of oxidative stress in occurrence of relapses in multiple sclerosis: the spectrum of oxidatively modified serum proteins detected by proteomics and redox proteomics analysis,” PLoS ONE, vol. 8, no. 6, article e65184, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. T. Kalincik, “Multiple sclerosis relapses: epidemiology, outcomes and management. A systematic review,” Neuroepidemiology, vol. 44, no. 4, pp. 199–214, 2015. View at Publisher · View at Google Scholar · View at Scopus
  3. A. Compston and A. Coles, “Multiple sclerosis,” The Lancet, vol. 372, no. 9648, pp. 1502–1517, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. B. D. Trapp, R. Ransohoff, and R. Rudick, “Axonal pathology in multiple sclerosis: relationship to neurologic disability,” Current Opinion in Neurology, vol. 12, no. 3, pp. 295–302, 1999. View at Publisher · View at Google Scholar · View at Scopus
  5. B. D. Trapp, J. Peterson, R. M. Ransohoff, R. Rudick, S. Mörk, and L. Bö, “Axonal transection in the lesions of multiple sclerosis,” The New England Journal of Medicine, vol. 338, no. 5, pp. 278–285, 1998. View at Publisher · View at Google Scholar · View at Scopus
  6. R. E. Gonsette, “Neurodegeneration in multiple sclerosis: the role of oxidative stress and excitotoxicity,” Journal of the Neurological Sciences, vol. 274, no. 1-2, pp. 48–53, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. E. Miller, A. Walczak, J. Saluk, M. B. Ponczek, and I. Majsterek, “Oxidative modification of patient's plasma proteins and its role in pathogenesis of multiple sclerosis,” Clinical Biochemistry, vol. 45, no. 1-2, pp. 26–30, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. R. Kohen and A. Nyska, “Oxidation of biological systems: Oxidative stress phenomena, antioxidants, redox reactions, and methods for their quantification,” Toxicologic Pathology, vol. 30, no. 6, pp. 620–650, 2002. View at Publisher · View at Google Scholar · View at Scopus
  9. M. McIntyre, D. F. Bohr, and A. F. Dominiczak, “Endothelial function in hypertension: the role of superoxide anion,” Hypertension, vol. 34, no. 4 I, pp. 539–545, 1999. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Genestra, “Oxyl radicals, redox-sensitive signalling cascades and antioxidants,” Cellular Signalling, vol. 19, no. 9, pp. 1807–1819, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. D. E. Koshland Jr., “The molecule of the year,” Science, vol. 258, no. 5090, p. 1861, 1992. View at Publisher · View at Google Scholar · View at Scopus
  12. M. A. Friese, B. Schattling, and L. Fugger, “Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis,” Nature Reviews Neurology, vol. 10, no. 4, pp. 225–238, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. E. Miller, “Myostimulation as an antloxldatlve factor in sclerosis multiplex,” Polski Merkuriusz Lekarski, vol. 31, no. 183, pp. 186–189, 2011. View at Google Scholar · View at Scopus
  14. J. R. Plemel, C. A. Juzwik, C. A. Benson, M. Monks, C. Harris, and M. Ploughman, “Over-the-counter anti-oxidant therapies for use in multiple sclerosis: a systematic review,” Multiple Sclerosis, vol. 21, no. 12, pp. 1485–1495, 2015. View at Publisher · View at Google Scholar · View at Scopus
  15. F. Kees, “Dimethyl fumarate: a Janus-faced substance?” Expert Opinion on Pharmacotherapy, vol. 14, no. 11, pp. 1559–1567, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. X. Zhang, M. Haaf, B. Todorich et al., “Cytokine toxicity to oligodendrocyte precursors is mediated by iron,” Glia, vol. 52, no. 3, pp. 199–208, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. B. Halliwell, “Oxidants and human disease: some new concepts,” The FASEB Journal, vol. 1, no. 5, pp. 358–364, 1987. View at Google Scholar · View at Scopus
  18. A. Phaniendra, D. B. Jestadi, and L. Periyasamy, “Free radicals: properties, sources, targets, and their implication in various diseases,” Indian Journal of Clinical Biochemistry, vol. 30, no. 1, pp. 11–26, 2015. View at Publisher · View at Google Scholar
  19. P. Kuppusamy and J. L. Zweier, “Characterization of free radical generation by xanthine oxidase. Evidence for hydroxyl radical generation,” The Journal of Biological Chemistry, vol. 264, no. 17, pp. 9880–9884, 1989. View at Google Scholar · View at Scopus
  20. L. Haider, C. Simeonidou, G. Steinberger et al., “Multiple sclerosis deep grey matter: the relation between demyelination, neurodegeneration, inflammation and iron,” Journal of Neurology, Neurosurgery, and Psychiatry, vol. 85, no. 12, pp. 1386–1395, 2014. View at Publisher · View at Google Scholar · View at Scopus
  21. H. A. Kontos, E. P. Wei, E. F. Ellis et al., “Appearance of superoxide anion radical in cerebral extracellular space during increased prostaglandin synthesis in cats,” Circulation Research, vol. 57, no. 1, pp. 142–151, 1985. View at Publisher · View at Google Scholar · View at Scopus
  22. L. Haider, “Inflammation, iron, energy failure, and oxidative stress in the pathogenesis of multiple sclerosis,” Oxidative Medicine and Cellular Longevity, vol. 2015, Article ID 725370, 10 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  23. F. Darios, N. Lambeng, J.-D. Troadec, P. P. Michel, and M. Ruberg, “Ceramide increases mitochondrial free calcium levels via caspase 8 and Bid: role in initiation of cell death,” Journal of Neurochemistry, vol. 84, no. 4, pp. 643–654, 2003. View at Publisher · View at Google Scholar · View at Scopus
  24. T. Douki and J. Cadet, “Peroxynitrite mediated oxidation of purine bases of nucleosides and isolated DNA,” Free Radical Research, vol. 24, no. 5, pp. 369–380, 1996. View at Publisher · View at Google Scholar · View at Scopus
  25. Ľ. Kuračka, T. Kalnovičová, J. Kucharská, and P. Turčáni, “Multiple sclerosis: evaluation of purine nucleotide metabolism in central nervous system in association with serum levels of selected fat-soluble antioxidants,” Multiple Sclerosis International, vol. 2014, Article ID 759808, 9 pages, 2014. View at Publisher · View at Google Scholar
  26. H. Lassmann, J. Van Horssen, and D. Mahad, “Progressive multiple sclerosis: pathology and pathogenesis,” Nature Reviews Neurology, vol. 8, no. 11, pp. 647–656, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. I. Dujmovic, T. Pekmezovic, R. Obrenovic et al., “Cerebrospinal fluid and serum uric acid levels in patients with multiple sclerosis,” Clinical Chemistry and Laboratory Medicine, vol. 47, no. 7, pp. 848–853, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. V. V. Bamm, D. K. Lanthier, E. L. Stephenson, G. S. T. Smith, and G. Harauz, “In vitro study of the direct effect of extracellular hemoglobin on myelin components,” Biochimica et Biophysica Acta—Molecular Basis of Disease, vol. 1852, no. 1, pp. 92–103, 2015. View at Publisher · View at Google Scholar · View at Scopus
  29. B. Halliwell, M. V. Clement, and L. H. Long, “Hydrogen peroxide in the human body,” FEBS Letters, vol. 486, no. 1, pp. 10–13, 2000. View at Publisher · View at Google Scholar · View at Scopus
  30. A. A. Starkov, “The role of mitochondria in reactive oxygen species metabolism and signaling,” Annals of the New York Academy of Sciences, vol. 1147, pp. 37–52, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. A. N. Carvalho, J. L. Lim, P. G. Nijland, M. E. Witte, and J. Van Horssen, “Glutathione in multiple sclerosis: more than just an antioxidant?” Multiple Sclerosis Journal, vol. 20, no. 11, pp. 1425–1431, 2014. View at Publisher · View at Google Scholar · View at Scopus
  32. I. Sadowska-Bartosz, M. Adamczyk-Sowa, A. Gajewska, and G. Bartosz, “Oxidative modification of blood serum proteins in multiple sclerosis after interferon or mitoxantrone treatment,” Journal of Neuroimmunology, vol. 266, no. 1-2, pp. 67–74, 2014. View at Publisher · View at Google Scholar · View at Scopus
  33. F. Bagnato, S. Hametner, B. Yao et al., “Tracking iron in multiple sclerosis: a combined imaging and histopathological study at 7 Tesla,” Brain, vol. 134, no. 12, pp. 3602–3615, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. S. Rossi, C. Motta, V. Studer et al., “Tumor necrosis factor is elevated in progressive multiple sclerosis and causes excitotoxic neurodegeneration,” Multiple Sclerosis Journal, vol. 20, no. 3, pp. 304–312, 2014. View at Publisher · View at Google Scholar · View at Scopus
  35. K. Marballi, M. P. Quinones, F. Jimenez et al., “In vivo and in vitro genetic evidence of involvement of neuregulin 1 in immune system dysregulation,” Journal of Molecular Medicine, vol. 88, no. 11, pp. 1133–1141, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. J. W. Hill, R. Poddar, J. F. Thompson, G. A. Rosenberg, and Y. Yang, “Intranuclear matrix metalloproteinases promote DNA damage and apoptosis induced by oxygen-glucose deprivation in neurons,” Neuroscience, vol. 220, pp. 277–290, 2012. View at Publisher · View at Google Scholar · View at Scopus
  37. C. Tronel, G. Y. Rochefort, N. Arlicot, S. Bodard, S. Chalon, and D. Antier, “Oxidative stress is related to the deleterious effects of heme oxygenase-1 in an in vivo neuroinflammatory rat model,” Oxidative Medicine and Cellular Longevity, vol. 2013, Article ID 264935, 10 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  38. A. Alexoudi, S. Zachaki, C. Stavropoulou et al., “Combined GSTP1 and NQO1 germline polymorphisms in the susceptibility to Multiple Sclerosis,” International Journal of Neuroscience, vol. 125, no. 1, pp. 32–37, 2015. View at Publisher · View at Google Scholar · View at Scopus
  39. A. Falluel-Morel, N. Aubert, D. Vaudry et al., “Opposite regulation of the mitochondrial apoptotic pathway by C2-ceramide and PACAP through a MAP-kinase-dependent mechanism in cerebellar granule cells,” Journal of Neurochemistry, vol. 91, no. 5, pp. 1231–1243, 2004. View at Publisher · View at Google Scholar · View at Scopus
  40. S. Rossi, R. Furlan, V. De Chiara et al., “Interleukin-1β causes synaptic hyperexcitability in multiple sclerosis,” Annals of Neurology, vol. 71, no. 1, pp. 76–83, 2012. View at Publisher · View at Google Scholar · View at Scopus
  41. D. Mahad, H. Lassmann, and D. Turnbull, “Review: mitochondria and disease progression in multiple sclerosis,” Neuropathology and Applied Neurobiology, vol. 34, no. 6, pp. 577–589, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. C. R. N. Polachini, R. M. Spanevello, D. Zanini et al., “Evaluation of delta-aminolevulinic dehydratase activity, oxidative stress biomarkers, and vitamin D levels in patients with multiple sclerosis,” Neurotoxicity Research, vol. 29, no. 2, pp. 230–242, 2016. View at Publisher · View at Google Scholar · View at Scopus
  43. M. Chevion, E. Berenshtein, and E. R. Stadtman, “Human studies related to protein oxidation: protein carbonyl content as a marker of damage,” Free Radical Research, vol. 33, pp. S99–S108, 2000. View at Google Scholar · View at Scopus
  44. P. G. Nijland, M. E. Witte, B. van het Hof et al., “Astroglial PGC-1alpha increases mitochondrial antioxidant capacity and suppresses inflammation: implications for multiple sclerosis,” Acta Neuropathologica Communications, vol. 2, no. 1, article 170, 2014. View at Publisher · View at Google Scholar
  45. A. Kirbas, S. Kirbas, O. Anlar, H. Efe, and A. Yilmaz, “Serum paraoxonase and arylesterase activity and oxidative status in patients with multiple sclerosis,” Journal of Clinical Neuroscience, vol. 20, no. 8, pp. 1106–1109, 2013. View at Publisher · View at Google Scholar · View at Scopus
  46. M. A. Lutsky, A. M. Zemskov, and K. A. Razinkin, “[Biochemical markers of oxidative stress in different forms and phases of multiple sclerosis],” Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova / Ministerstvo zdravookhraneniia i meditsinskoĭ promyshlennosti Rossiĭskoĭ Federatsii, Vserossiĭskoe obshchestvo nevrologov [i] Vserossiĭskoe obshchestvo psikhiatrov, vol. 114, no. 11, pp. 74–77, 2014. View at Google Scholar · View at Scopus
  47. I. Tasset, C. Bahamonde, E. Agüera et al., “Effect of natalizumab on oxidative damage biomarkers in relapsing-remitting multiple sclerosis,” Pharmacological Reports, vol. 65, no. 3, pp. 624–631, 2013. View at Publisher · View at Google Scholar · View at Scopus
  48. O. Binyamin, L. Larush, K. Frid et al., “Treatment of a multiple sclerosis animal model by a novel nanodrop formulation of a natural antioxidant,” International Journal of Nanomedicine, vol. 10, pp. 7165–7174, 2015. View at Publisher · View at Google Scholar · View at Scopus
  49. K.-C. Wang, C.-P. Tsai, C.-L. Lee et al., “α-lipoic acid enhances endogenous peroxisome-proliferator-activated receptor-γ to ameliorate experimental autoimmune encephalomyelitis in mice,” Clinical Science, vol. 125, no. 7, pp. 329–340, 2013. View at Publisher · View at Google Scholar · View at Scopus
  50. S. A. Ganie, T. A. Dar, A. H. Bhat et al., “Melatonin: a potential anti-oxidant therapeutic agent for mitochondrial dysfunctions and related disorders,” Rejuvenation Research, vol. 19, no. 1, pp. 21–40, 2016. View at Publisher · View at Google Scholar · View at Scopus
  51. J. Tenorio-Laranga, I. Peltonen, S. Keskitalo et al., “Alteration of prolyl oligopeptidase and activated α-2-macroglobulin in multiple sclerosis subtypes and in the clinically isolated syndrome,” Biochemical Pharmacology, vol. 85, no. 12, pp. 1783–1794, 2013. View at Publisher · View at Google Scholar · View at Scopus
  52. C. B. Burness and E. D. Deeks, “Dimethyl fumarate: a review of its use in patients with relapsing-remitting multiple sclerosis,” CNS Drugs, vol. 28, no. 4, pp. 373–387, 2014. View at Publisher · View at Google Scholar · View at Scopus
  53. A. Zarrouk, T. Nury, E. M. Karym et al., “Attenuation of 7-ketocholesterol-induced overproduction of reactive oxygen species, apoptosis, and autophagy by dimethyl fumarate on 158 N murine oligodendrocytes,” The Journal of Steroid Biochemistry and Molecular Biology, 2016. View at Publisher · View at Google Scholar
  54. P. Wang, K. Xie, C. Wang, and J. Bi, “Oxidative stress induced by lipid peroxidation is related with inflammation of demyelination and neurodegeneration in multiple sclerosis,” European Neurology, vol. 72, no. 3-4, pp. 249–254, 2014. View at Publisher · View at Google Scholar · View at Scopus
  55. I. Sadowska-Bartosz, M. Adamczyk-Sowa, S. Galiniak, S. Mucha, K. Pierzchala, and G. Bartosz, “Oxidative modification of serum proteins in multiple sclerosis,” Neurochemistry International, vol. 63, no. 5, pp. 507–516, 2013. View at Publisher · View at Google Scholar · View at Scopus
  56. M. T. Fischer, R. Sharma, J. L. Lim et al., “NADPH oxidase expression in active multiple sclerosis lesions in relation to oxidative tissue damage and mitochondrial injury,” Brain, vol. 135, no. 3, pp. 886–899, 2012. View at Publisher · View at Google Scholar · View at Scopus
  57. V. V. Bamm and G. Harauz, “Hemoglobin as a source of iron overload in multiple sclerosis: does multiple sclerosis share risk factors with vascular disorders?” Cellular and Molecular Life Sciences, vol. 71, no. 10, pp. 1789–1798, 2014. View at Publisher · View at Google Scholar · View at Scopus
  58. N. Liu, Q.-C. Kan, X.-J. Zhang et al., “Upregulation of immunomodulatory molecules by matrine treatment in experimental autoimmune encephalomyelitis,” Experimental and Molecular Pathology, vol. 97, no. 3, pp. 470–476, 2014. View at Publisher · View at Google Scholar · View at Scopus
  59. M. Tully and R. Shi, “New insights in the pathogenesis of multiple sclerosis-role of acrolein in neuronal and myelin damage,” International Journal of Molecular Sciences, vol. 14, no. 10, pp. 20037–20047, 2013. View at Publisher · View at Google Scholar · View at Scopus
  60. J. Correale, “The role of microglial activation in disease progression,” Multiple Sclerosis, vol. 20, no. 10, pp. 1288–1295, 2014. View at Publisher · View at Google Scholar · View at Scopus
  61. J. S. Beckman and W. H. Koppenol, “Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and the ugly,” The American Journal of Physiology, vol. 271, no. 5, pp. C1424–C1437, 1996. View at Google Scholar · View at Scopus
  62. A. A. Mossakowski, J. Pohlan, D. Bremer et al., “Tracking CNS and systemic sources of oxidative stress during the course of chronic neuroinflammation,” Acta Neuropathologica, vol. 130, no. 6, pp. 799–814, 2015. View at Publisher · View at Google Scholar · View at Scopus
  63. O. Errea, B. Moreno, A. Gonzalez-Franquesa, P. M. Garcia-Roves, and P. Villoslada, “The disruption of mitochondrial axonal transport is an early event in neuroinflammation,” Journal of Neuroinflammation, vol. 12, article 152, 2015. View at Publisher · View at Google Scholar · View at Scopus
  64. H. Lassmann, “Pathology and disease mechanisms in different stages of multiple sclerosis,” Journal of the Neurological Sciences, vol. 333, no. 1-2, pp. 1–4, 2013. View at Publisher · View at Google Scholar · View at Scopus
  65. H. Bros, J. M. Millward, F. Paul, R. Niesner, and C. Infante-Duarte, “Oxidative damage to mitochondria at the nodes of Ranvier precedes axon degeneration in ex vivo transected axons,” Experimental Neurology, vol. 261, pp. 127–135, 2014. View at Publisher · View at Google Scholar · View at Scopus
  66. W. Dröge, “Free radicals in the physiological control of cell function,” Physiological Reviews, vol. 82, no. 1, pp. 47–95, 2002. View at Publisher · View at Google Scholar · View at Scopus
  67. M. Valko, D. Leibfritz, J. Moncol, M. T. D. Cronin, M. Mazur, and J. Telser, “Free radicals and antioxidants in normal physiological functions and human disease,” International Journal of Biochemistry and Cell Biology, vol. 39, no. 1, pp. 44–84, 2007. View at Publisher · View at Google Scholar · View at Scopus
  68. J. Nordberg and E. S. J. Arnér, “Reactive oxygen species, antioxidants, and the mammalian thioredoxin system,” Free Radical Biology and Medicine, vol. 31, no. 11, pp. 1287–1312, 2001. View at Publisher · View at Google Scholar · View at Scopus
  69. B. Halliwell, Free Radicals and Other Reactive Species in Disease, National University of Singapore, 2001.
  70. D. H. Mahad, B. D. Trapp, and H. Lassmann, “Pathological mechanisms in progressive multiple sclerosis,” The Lancet Neurology, vol. 14, no. 2, pp. 183–193, 2015. View at Publisher · View at Google Scholar · View at Scopus
  71. L. Haider, M. T. Fischer, J. M. Frischer et al., “Oxidative damage in multiple sclerosis lesions,” Brain, vol. 134, no. 7, pp. 1914–1924, 2011. View at Publisher · View at Google Scholar · View at Scopus
  72. E. H. J. M. Jansen and T. Ruskovska, “Comparative analysis of serum (Anti)oxidative status para Cyrillicmeters in healthy persons,” International Journal of Molecular Sciences, vol. 14, no. 3, pp. 6106–6115, 2013. View at Publisher · View at Google Scholar · View at Scopus
  73. M. Karlík, P. Valkovič, V. Hančinová, L. Krížová, Ľ. Tóthová, and P. Celec, “Markers of oxidative stress in plasma and saliva in patients with multiple sclerosis,” Clinical Biochemistry, vol. 48, no. 1-2, pp. 24–28, 2015. View at Publisher · View at Google Scholar
  74. E. Miller, A. Walczak, I. Majsterek, and J. Kedziora, “Melatonin reduces oxidative stress in the erythrocytes of multiple sclerosis patients with secondary progressive clinical course,” Journal of Neuroimmunology, vol. 257, no. 1-2, pp. 97–101, 2013. View at Publisher · View at Google Scholar · View at Scopus
  75. S. Ljubisavljevic, I. Stojanovic, T. Cvetkovic et al., “Erythrocytes' antioxidative capacity as a potential marker of oxidative stress intensity in neuroinflammation,” Journal of the Neurological Sciences, vol. 337, no. 1-2, pp. 8–13, 2014. View at Publisher · View at Google Scholar · View at Scopus
  76. V. Chiurchiù, “Novel targets in multiple sclerosis: to oxidative stress and beyond,” Current Topics in Medicinal Chemistry, vol. 14, no. 22, pp. 2590–2599, 2014. View at Publisher · View at Google Scholar · View at Scopus
  77. E. Sbardella, A. Greco, M. L. Stromillo et al., “Isoprostanes in clinically isolated syndrome and early multiple sclerosis as biomarkers of tissue damage and predictors of clinical course,” Multiple Sclerosis Journal, vol. 19, no. 4, pp. 411–417, 2013. View at Publisher · View at Google Scholar · View at Scopus
  78. O. G. Vidaurre, J. D. Haines, I. Katz Sand et al., “Cerebrospinal fluid ceramides from patients with multiple sclerosis impair neuronal bioenergetics,” Brain, vol. 137, no. 8, pp. 2271–2286, 2014. View at Publisher · View at Google Scholar · View at Scopus
  79. B. Parajuli, H. Horiuchi, T. Mizuno, H. Takeuchi, and A. Suzumura, “CCL11 enhances excitotoxic neuronal death by producing reactive oxygen species in microglia,” GLIA, vol. 63, no. 12, pp. 2274–2284, 2015. View at Publisher · View at Google Scholar · View at Scopus
  80. S. Ljubisavljevic, I. Stojanovic, S. Vojinovic et al., “The patients with clinically isolated syndrome and relapsing remitting multiple sclerosis show different levels of advanced protein oxidation products and total thiol content in plasma and CSF,” Neurochemistry International, vol. 62, no. 7, pp. 988–997, 2013. View at Publisher · View at Google Scholar · View at Scopus
  81. J.-Z. Guan, W.-P. Guan, T. Maeda, X. Guoqing, W. GuangZhi, and N. Makino, “Patients with multiple sclerosis show increased oxidative stress markers and somatic telomere length shortening,” Molecular and Cellular Biochemistry, vol. 400, no. 1-2, pp. 183–187, 2015. View at Publisher · View at Google Scholar · View at Scopus
  82. M. Tully, L. Zheng, and R. Shi, “Acrolein detection: potential theranostic utility in multiple sclerosis and spinal cord injury,” Expert Review of Neurotherapeutics, vol. 14, no. 6, pp. 679–685, 2014. View at Publisher · View at Google Scholar · View at Scopus
  83. A. P. Kallaur, E. M. V. Reiche, S. R. Oliveira et al., “Genetic, immune-inflammatory, and oxidative stress biomarkers as predictors for disability and disease progression in multiple sclerosis,” Molecular Neurobiology, 2016. View at Publisher · View at Google Scholar · View at Scopus
  84. J. Ivica and J. Wilhelm, “Lipophilic fluorescent products of free radicals,” Biomedical Papers, vol. 158, no. 3, pp. 365–372, 2014. View at Publisher · View at Google Scholar · View at Scopus
  85. S. R. Oliveira, A. N. Colado Simão, A. P. Kallaur et al., “Disability in patients with multiple sclerosis: influence of insulin resistance, adiposity, and oxidative stress,” Nutrition, vol. 30, no. 3, pp. 268–273, 2014. View at Publisher · View at Google Scholar · View at Scopus
  86. M. Arnold, R. Bissinger, and F. Lang, “Mitoxantrone-induced suicidal erythrocyte death,” Cellular Physiology and Biochemistry, vol. 34, no. 5, pp. 1756–1767, 2014. View at Publisher · View at Google Scholar · View at Scopus
  87. L. Pasquali, C. Pecori, C. Lucchesi et al., “Plasmatic oxidative stress biomarkers in multiple sclerosis: relation with clinical and demographic characteristics,” Clinical Biochemistry, vol. 48, no. 1-2, pp. 19–23, 2015. View at Publisher · View at Google Scholar · View at Scopus
  88. R. Shi, T. Rickett, and W. Sun, “Acrolein-mediated injury in nervous system trauma and diseases,” Molecular Nutrition and Food Research, vol. 55, no. 9, pp. 1320–1331, 2011. View at Publisher · View at Google Scholar · View at Scopus
  89. P. Kharel, J. McDonough, and S. Basu, “Evidence of extensive RNA oxidation in normal appearing cortex of multiple sclerosis brain,” Neurochemistry International, vol. 92, pp. 43–48, 2016. View at Publisher · View at Google Scholar · View at Scopus
  90. A. Morel, M. Bijak, E. Miller, J. Rywaniak, S. Miller, and J. Saluk, “Relationship between the increased haemostatic properties of blood platelets and oxidative stress level in multiple sclerosis patients with the secondary progressive stage,” Oxidative Medicine and Cellular Longevity, vol. 2015, Article ID 240918, 10 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  91. S. Ljubisavljevic, “Oxidative stress and neurobiology of demyelination,” Molecular Neurobiology, vol. 53, no. 1, pp. 744–758, 2016. View at Publisher · View at Google Scholar · View at Scopus
  92. J. M. Matés, C. Pérez-Gómez, and I. N. De Castro, “Antioxidant enzymes and human diseases,” Clinical Biochemistry, vol. 32, no. 8, pp. 595–603, 1999. View at Publisher · View at Google Scholar · View at Scopus
  93. H. Z. Chae, S. W. Kang, and S. G. Rhee, “Isoforms of mammalian peroxiredoxin that reduce peroxides in presence of thioredoxin,” Methods in Enzymology, vol. 300, pp. 219–226, 1999. View at Publisher · View at Google Scholar · View at Scopus
  94. M. S. E. Aleagha, B. Siroos, M. Ahmadi et al., “Decreased concentration of Klotho in the cerebrospinal fluid of patients with relapsing-remitting multiple sclerosis,” Journal of Neuroimmunology, vol. 281, pp. 5–8, 2015. View at Publisher · View at Google Scholar · View at Scopus
  95. C. Cervellati, A. Romani, E. Fainardi et al., “Serum ferroxidase activity in patients with multiple sclerosis: A Pilot Study,” In Vivo, vol. 28, no. 6, pp. 1197–1200, 2014. View at Google Scholar · View at Scopus
  96. T. Gholipour, T. Ghazizadeh, S. Babapour et al., “Decreased urinary level of melatonin as a marker of disease severity in patients with multiple sclerosis,” Iranian Journal of Allergy, Asthma and Immunology, vol. 14, no. 1, pp. 91–97, 2015. View at Google Scholar · View at Scopus
  97. A. Ceriello, N. Bortolotti, E. Falleti et al., “Total radical-trapping antioxidant parameter in NIDDM patients,” Diabetes Care, vol. 20, no. 2, pp. 194–197, 1997. View at Publisher · View at Google Scholar · View at Scopus
  98. M. Gironi, B. Borgiani, E. Mariani et al., “Oxidative stress is differentially present in multiple sclerosis courses, early evident, and unrelated to treatment,” Journal of Immunology Research, vol. 2014, Article ID 961863, 9 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  99. E. Miller, A. Morel, L. Saso, and J. Saluk, “Melatonin redox activity. Its potential clinical applications in neurodegenerative disorders,” Current Topics in Medicinal Chemistry, vol. 15, no. 2, pp. 163–169, 2015. View at Publisher · View at Google Scholar · View at Scopus
  100. S. Emamgholipour, A. Hossein-Nezhad, M. A. Sahraian, F. Askarisadr, and M. Ansari, “Evidence for possible role of melatonin in reducing oxidative stress in multiple sclerosis through its effect on SIRT1 and antioxidant enzymes,” Life Sciences, vol. 145, pp. 34–41, 2016. View at Publisher · View at Google Scholar · View at Scopus
  101. A. Salemme, A. R. Togna, A. Mastrofrancesco et al., “Anti-inflammatory effects and antioxidant activity of dihydroasparagusic acid in lipopolysaccharide-activated microglial cells,” Brain Research Bulletin, vol. 120, pp. 151–158, 2016. View at Publisher · View at Google Scholar · View at Scopus
  102. G. Morris, K. Walder, B. K. Puri, M. Berk, and M. Maes, “The deleterious effects of oxidative and nitrosative stress on palmitoylation, membrane lipid rafts and lipid-based cellular signalling: new drug targets in neuroimmune disorders,” Molecular Neurobiology, vol. 53, no. 7, pp. 4638–4658, 2016. View at Publisher · View at Google Scholar · View at Scopus
  103. M. Khalili, S. Eghtesadi, A. Mirshafiey et al., “Effect of lipoic acid consumption on oxidative stress among multiple sclerosis patients: a randomized controlled clinical trial,” Nutritional Neuroscience, vol. 17, no. 1, pp. 16–20, 2014. View at Publisher · View at Google Scholar · View at Scopus
  104. M. Sanoobar, S. Eghtesadi, A. Azimi, M. Khalili, S. Jazayeri, and M. Reza Gohari, “Coenzyme Q10 supplementation reduces oxidative stress and increases antioxidant enzyme activity in patients with relapsing-remitting multiple sclerosis,” The International Journal of Neuroscience, vol. 123, no. 11, pp. 776–782, 2013. View at Publisher · View at Google Scholar · View at Scopus
  105. S. M. Fiebiger, H. Bros, T. Grobosch et al., “The antioxidant idebenone fails to prevent or attenuate chronic experimental autoimmune encephalomyelitis in the mouse,” Journal of Neuroimmunology, vol. 262, no. 1-2, pp. 66–71, 2013. View at Publisher · View at Google Scholar · View at Scopus
  106. S. Ghaffari, H. Hatami, and G. Dehghan, “Saffron ethanolic extract attenuates oxidative stress, spatial learning, and memory impairments induced by local injection of ethidium bromide,” Research in Pharmaceutical Sciences, vol. 10, no. 3, pp. 222–232, 2015. View at Google Scholar · View at Scopus
  107. N. A. Noor, H. M. Fahmy, F. F. Mohammed, A. A. Elsayed, and N. M. Radwan, “Nigella sativa amliorates inflammation and demyelination in the experimental autoimmune encephalomyelitis-induced Wistar rats,” International Journal of Clinical and Experimental Pathology, vol. 8, no. 6, pp. 6269–6286, 2015. View at Google Scholar · View at Scopus
  108. W.-Y. Ong, T. Farooqui, G. Kokotos, and A. A. Farooqui, “Syntheti and natural inhibitors of phospholipases A2: their importance for understanding and treatment of neurological disorders,” ACS Chemical Neuroscience, vol. 6, no. 6, pp. 814–831, 2015. View at Publisher · View at Google Scholar · View at Scopus
  109. M. Naziroglu, S. Kutluhan, I. S. Övey, M. Aykur, and V. A. Yurekli, “Modulation of oxidative stress, apoptosis, and calcium entry in leukocytes of patients with multiple sclerosis by Hypericum perforatum,” Nutritional Neuroscience, vol. 17, no. 5, pp. 214–221, 2014. View at Publisher · View at Google Scholar · View at Scopus
  110. E. Mauriz, A. Laliena, D. Vallejo et al., “Effects of a low-fat diet with antioxidant supplementation on biochemical markers of multiple sclerosis long-term care residents,” Nutricion Hospitalaria, vol. 28, no. 6, pp. 2229–2235, 2013. View at Publisher · View at Google Scholar · View at Scopus
  111. V. P. Dadhania, P. P. Trivedi, A. Vikram, and D. N. Tripathi, “Nutraceuticals against neurodegeneration: a mechanistic insight,” Current Neuropharmacology, vol. 14, no. 6, pp. 627–640, 2016. View at Publisher · View at Google Scholar
  112. L. González-González, J. G. Pérez-Cortéz, M. Flores-Aldana, N. Macías-Morales, and C. Hernández-Girón, “Antioxidant use as dietary therapy in patients with multiple sclerosis,” Medwave, vol. 15, no. 1, Article ID e6065, 2015. View at Publisher · View at Google Scholar · View at Scopus
  113. J. J. A. Hendriks, H. E. De Vries, S. M. A. Van Der Pol, T. K. Van Den Berg, E. A. F. Van Tol, and C. D. Dijkstra, “Flavonoids inhibit myelin phagocytosis by macrophages; a structure-activity relationship study,” Biochemical Pharmacology, vol. 65, no. 5, pp. 877–885, 2003. View at Publisher · View at Google Scholar · View at Scopus
  114. K. L. Heckman, W. Decoteau, A. Estevez et al., “Custom cerium oxide nanoparticles protect against a free radical mediated autoimmune degenerative disease in the brain,” ACS Nano, vol. 7, no. 12, pp. 10582–10596, 2013. View at Publisher · View at Google Scholar · View at Scopus
  115. B. Li, W. Cui, J. Liu et al., “Sulforaphane ameliorates the development of experimental autoimmune encephalomyelitis by antagonizing oxidative stress and Th17-related inflammation in mice,” Experimental Neurology, vol. 250, pp. 239–249, 2013. View at Publisher · View at Google Scholar · View at Scopus
  116. S. Rezapour-Firouzi, S. R. Arefhosseini, M. Ebrahimi-Mamaghani et al., “Activity of liver enzymes in multiple sclerosis patients with Hot-nature diet and co-supplemented hemp seed, evening primrose oils intervention,” Complementary Therapies in Medicine, vol. 22, no. 6, pp. 986–993, 2014. View at Publisher · View at Google Scholar · View at Scopus
  117. N. Scolding, R. Franklin, S. Stevens, C.-H. Heldin, A. Compston, and J. Newcombe, “Oligodendrocyte progenitors are present in the normal adult human CNS and in the lesions of multiple sclerosis,” Brain, vol. 121, no. 12, pp. 2221–2228, 1998. View at Publisher · View at Google Scholar · View at Scopus
  118. M. Bonora, E. De Marchi, S. Patergnani et al., “Tumor necrosis factor-α impairs oligodendroglial differentiation through a mitochondria-dependent process,” Cell Death and Differentiation, vol. 21, no. 8, pp. 1198–1208, 2014. View at Publisher · View at Google Scholar · View at Scopus
  119. T. Kuhlmann, V. Miron, Q. Cuo, C. Wegner, J. Antel, and W. Brück, “Differentiation block of oligodendroglial progenitor cells as a cause for remyelination failure in chronic multiple sclerosis,” Brain, vol. 131, no. 7, pp. 1749–1758, 2008. View at Publisher · View at Google Scholar · View at Scopus
  120. G. Wolswijk, “Oligodendrocyte precursor cells in the demyelinated multiple sclerosis spinal cord,” Brain, vol. 125, no. 2, pp. 338–349, 2002. View at Publisher · View at Google Scholar · View at Scopus
  121. O. Maier, R. Fischer, C. Agresti, and K. Pfizenmaier, “TNF receptor 2 protects oligodendrocyte progenitor cells against oxidative stress,” Biochemical and Biophysical Research Communications, vol. 440, no. 2, pp. 336–341, 2013. View at Publisher · View at Google Scholar · View at Scopus
  122. S. EL Andaloussi, S. Lakhal, I. Mäger, and M. J. A. Wood, “Exosomes for targeted siRNA delivery across biological barriers,” Advanced Drug Delivery Reviews, vol. 65, no. 3, pp. 391–397, 2013. View at Publisher · View at Google Scholar · View at Scopus
  123. A. D. Pusic, K. M. Pusic, B. L. L. Clayton, and R. P. Kraig, “IFNγ-stimulated dendritic cell exosomes as a potential therapeutic for remyelination,” Journal of Neuroimmunology, vol. 266, no. 1-2, pp. 12–23, 2014. View at Publisher · View at Google Scholar · View at Scopus
  124. R. Gold, C. Linington, and H. Lassmann, “Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research,” Brain, vol. 129, no. 8, pp. 1953–1971, 2006. View at Publisher · View at Google Scholar · View at Scopus
  125. K. J. Smith, R. Kapoor, and P. A. Felts, “Demyelination: the role of reactive oxygen and nitrogen species,” Brain Pathology, vol. 9, no. 1, pp. 69–92, 1999. View at Google Scholar · View at Scopus
  126. G. Leung, W. Sun, L. Zheng, S. Brookes, M. Tully, and R. Shi, “Anti-acrolein treatment improves behavioral outcome and alleviates myelin damage in experimental autoimmune enchephalomyelitis mouse,” Neuroscience, vol. 173, pp. 150–155, 2011. View at Publisher · View at Google Scholar · View at Scopus
  127. K. Hamann, G. Nehrt, H. Ouyang, B. Duerstock, and R. Shi, “Hydralazine inhibits compression and acrolein-mediated injuries in ex vivo spinal cord,” Journal of Neurochemistry, vol. 104, no. 3, pp. 708–718, 2008. View at Publisher · View at Google Scholar · View at Scopus
  128. K. Hamann and R. Shi, “Acrolein scavenging: a potential novel mechanism of attenuating oxidative stress following spinal cord injury,” Journal of Neurochemistry, vol. 111, no. 6, pp. 1348–1356, 2009. View at Publisher · View at Google Scholar · View at Scopus
  129. P. K. Kamat, A. Kalani, P. Kyles, S. C. Tyagi, and N. Tyagi, “Autophagy of mitochondria: a promising therapeutic target for neurodegenerative disease,” Cell Biochemistry and Biophysics, vol. 70, no. 2, pp. 707–719, 2014. View at Publisher · View at Google Scholar · View at Scopus
  130. A. Abdanipour, T. Tiraihi, A. Noori-Zadeh, A. Majdi, and R. Gosaili, “Evaluation of lovastatin effects on expression of anti-apoptotic Nrf2 and PGC-1α genes in neural stem cells treated with hydrogen peroxide,” Molecular Neurobiology, vol. 49, no. 3, pp. 1364–1372, 2014. View at Publisher · View at Google Scholar · View at Scopus
  131. M. Schachter, “Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update,” Fundamental and Clinical Pharmacology, vol. 19, no. 1, pp. 117–125, 2005. View at Publisher · View at Google Scholar · View at Scopus
  132. C. Hölscher, “Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases,” The Journal of Endocrinology, vol. 221, no. 1, pp. T31–T41, 2014. View at Publisher · View at Google Scholar · View at Scopus
  133. C. Hölscher, “Potential role of glucagon-like peptide-1 (GLP-1) in neuroprotection,” CNS Drugs, vol. 26, no. 10, pp. 871–882, 2012. View at Publisher · View at Google Scholar · View at Scopus
  134. H. Zhang, A. Ray, N. M. Miller, D. Hartwig, K. A. Pritchard, and B. N. Dittel, “Inhibition of myeloperoxidase at the peak of experimental autoimmune encephalomyelitis restores blood-brain barrier integrity and ameliorates disease severity,” Journal of Neurochemistry, vol. 136, no. 4, pp. 826–836, 2016. View at Publisher · View at Google Scholar · View at Scopus
  135. H.-M. Yun, K.-R. Park, E.-C. Kim, and J. T. Hong, “PRDX6 controls multiple sclerosis by suppressing inflammation and blood brain barrier disruption,” Oncotarget, vol. 6, no. 25, pp. 20875–20884, 2015. View at Publisher · View at Google Scholar · View at Scopus
  136. I. R. Stojanovic, M. Kostic, and S. Ljubisavljevic, “The role of glutamate and its receptors in multiple sclerosis,” Journal of Neural Transmission, vol. 121, no. 8, pp. 945–955, 2014. View at Publisher · View at Google Scholar · View at Scopus
  137. M. T. Viscomi, L. Latini, E. Bisicchia, V. Sasso, and M. Molinari, “Remote degeneration: insights from the hemicerebellectomy model,” Cerebellum, vol. 14, no. 1, pp. 15–18, 2015. View at Publisher · View at Google Scholar · View at Scopus
  138. M. T. Viscomi and M. Molinari, “Remote neurodegeneration: multiple actors for one play,” Molecular Neurobiology, vol. 50, no. 2, pp. 368–389, 2014. View at Publisher · View at Google Scholar · View at Scopus
  139. P. Pacher and K. Mackie, “Interplay of cannabinoid 2 (CB2) receptors with nitric oxide synthases, oxidative and nitrative stress, and cell death during remote neurodegeneration,” Journal of Molecular Medicine, vol. 90, no. 4, pp. 347–351, 2012. View at Publisher · View at Google Scholar · View at Scopus
  140. H. Huang, A. Taraboletti, and L. P. Shriver, “Dimethyl fumarate modulates antioxidant and lipid metabolism in oligodendrocytes,” Redox Biology, vol. 5, pp. 169–175, 2015. View at Publisher · View at Google Scholar · View at Scopus
  141. Q. Wang, S. Chuikov, S. Taitano et al., “Dimethyl fumarate protects neural stem/progenitor cells and neurons from oxidative damage through Nrf2-ERK1/2 MAPK pathway,” International Journal of Molecular Sciences, vol. 16, no. 6, pp. 13885–13907, 2015. View at Publisher · View at Google Scholar · View at Scopus
  142. S. Licht-Mayer, I. Wimmer, S. Traffehn et al., “Cell type-specific Nrf2 expression in multiple sclerosis lesions,” Acta Neuropathologica, vol. 130, no. 2, pp. 263–277, 2015. View at Publisher · View at Google Scholar · View at Scopus
  143. T. Dehmel, M. Döbert, S. Pankratz et al., “Monomethylfumarate reduces in vitro migration of mononuclear cells,” Neurological Sciences, vol. 35, no. 7, pp. 1121–1125, 2014. View at Publisher · View at Google Scholar · View at Scopus
  144. I. Lastres-Becker, A. J. García-Yagüe, R. H. Scannevin et al., “Repurposing the NRF2 activator dimethyl fumarate as therapy against synucleinopathy in Parkinson's disease,” Antioxidants & Redox Signaling, vol. 25, no. 2, pp. 61–77, 2016. View at Publisher · View at Google Scholar
  145. S. E. Fiedler, A. R. Kerns, C. Tsang, V. Tsang, D. Bourdette, and S. Salinthone, “Dimethyl fumarate activates the prostaglandin EP2 receptor and stimulates cAMP signaling in human peripheral blood mononuclear cells,” Biochemical and Biophysical Research Communications, vol. 475, no. 1, pp. 19–24, 2016. View at Publisher · View at Google Scholar
  146. T. Kume, A. Suenaga, Y. Izumi, and A. Akaike, “Protective effect of dimethyl fumarate on an oxidative stress model induced by sodium nitroprusside in mice,” Biological & Pharmaceutical Bulletin, vol. 39, no. 6, pp. 1055–1059, 2016. View at Publisher · View at Google Scholar
  147. Y. Liu, J. Qiu, Z. Wang et al., “Dimethylfumarate alleviates early brain injury and secondary cognitive deficits after experimental subarachnoid hemorrhage via activation of Keap1-Nrf2-ARE system,” Journal of Neurosurgery, vol. 123, no. 4, pp. 915–923, 2015. View at Publisher · View at Google Scholar · View at Scopus
  148. R. Kunze, A. Urrutia, A. Hoffmann et al., “Dimethyl fumarate attenuates cerebral edema formation by protecting the blood-brain barrier integrity,” Experimental Neurology, vol. 266, pp. 99–111, 2015. View at Publisher · View at Google Scholar · View at Scopus
  149. C. To, C. S. Ringelberg, D. B. Royce et al., “Dimethyl fumarate and the oleanane triterpenoids, CDDO-imidazolide and CDDO-methyl ester, both activate the Nrf2 pathway but have opposite effects in the A/J model of lung carcinogenesis,” Carcinogenesis, vol. 36, no. 7, pp. 769–781, 2015. View at Publisher · View at Google Scholar · View at Scopus
  150. C. Schuh, I. Wimmer, S. Hametner et al., “Oxidative tissue injury in multiple sclerosis is only partly reflected in experimental disease models,” Acta Neuropathologica, vol. 128, no. 2, pp. 247–266, 2014. View at Publisher · View at Google Scholar · View at Scopus
  151. M. Serdar, J. Herz, K. Kempe et al., “Fingolimod protects against neonatal white matter damage and long-term cognitive deficits caused by hyperoxia,” Brain, Behavior, and Immunity, vol. 52, pp. 106–119, 2016. View at Publisher · View at Google Scholar · View at Scopus
  152. A. D. Pusic and R. P. Kraig, “Phasic treatment with interferon gamma stimulates release of exosomes that protect against spreading depression,” Journal of Interferon and Cytokine Research, vol. 35, no. 10, pp. 795–807, 2015. View at Publisher · View at Google Scholar · View at Scopus
  153. H. M. Schipper, D. Arnold, F. Grand'Maison et al., “Tolerability and safety of combined glatiramer acetate and N-acetylcysteine in relapsing-remitting multiple sclerosis,” Clinical Neuropharmacology, vol. 38, no. 4, pp. 127–131, 2015. View at Publisher · View at Google Scholar · View at Scopus
  154. C. G. Pascuan, E. H. Simon, A. M. Genaro, and M. L. Palumbo, “Involvement of nitric oxide in improving stress-induced behavioural alteration by glatiramer acetate treatment in female BALB/c mice,” Psychopharmacology, vol. 232, no. 9, pp. 1595–1605, 2015. View at Publisher · View at Google Scholar · View at Scopus
  155. M. Adamczyk-Sowa, K. Pierzchala, P. Sowa, R. Polaniak, M. Kukla, and M. Hartel, “Influence of melatonin supplementation on serum antioxidative properties and impact of the quality of life in multiple sclerosis patients,” Journal of Physiology and Pharmacology, vol. 65, no. 4, pp. 543–550, 2014. View at Google Scholar · View at Scopus
  156. M. Adamczyk-Sowa, K. Pierzchala, P. Sowa et al., “Melatonin acts as antioxidant and improves sleep in MS patients,” Neurochemical Research, vol. 39, no. 8, pp. 1585–1593, 2014. View at Publisher · View at Google Scholar · View at Scopus
  157. G. Pentón-Rol, N. Lagumersindez-Denis, L. Muzio et al., “Comparative neuroregenerative effects of C-phycocyanin and IFN-beta in a model of multiple sclerosis in mice,” Journal of Neuroimmune Pharmacology, vol. 11, no. 1, pp. 153–167, 2016. View at Publisher · View at Google Scholar · View at Scopus
  158. C. Bahamonde, C. Conde, E. Agüera et al., “Elevated melatonin levels in natalizumab-treated female patients with relapsing-remitting multiple sclerosis: Relationship to oxidative stress,” European Journal of Pharmacology, vol. 730, no. 1, pp. 26–30, 2014. View at Publisher · View at Google Scholar · View at Scopus
  159. I. Tasset, E. Agüera, F. Gascón et al., “Natalizumab and reduction of carbonylated proteins in patients with multiple sclerosis,” Revista de Neurologia, vol. 54, no. 8, pp. 449–452, 2012. View at Google Scholar · View at Scopus
  160. A. Jamroz-Wisniewska, J. Beltowski, Z. Stelmasiak, and H. Bartosik-Psujek, “Paraoxonase 1 activity in multiple sclerosis patients during mitoxantrone therapy,” Acta Neurologica Scandinavica, vol. 127, no. 6, pp. e33–e36, 2013. View at Publisher · View at Google Scholar · View at Scopus
  161. F. Molinari, V. Simonetti, M. Franzini et al., “Ozone autohemotherapy induces long-term cerebral metabolic changes in multiple sclerosis patients,” International Journal of Immunopathology and Pharmacology, vol. 27, no. 3, pp. 379–389, 2014. View at Google Scholar · View at Scopus
  162. N. A. Salem, N. Assaf, M. F. Ismail, Y. A. Khadrawy, and M. Samy, “Ozone therapy in ethidium bromide-induced demyelination in rats: possible protective effect,” Cellular and Molecular Neurobiology, vol. 36, no. 6, pp. 943–954, 2016. View at Publisher · View at Google Scholar · View at Scopus